Below are the most recent publications written about "Piperidines" by people in Profiles.
-
Luo M, Xiao H. Black Pepper and Dietary Lipids Synergistically Enhance Carotenoid Bioavailability: A Narrative Review. Nutr Rev. 2026 Jun 01; 84(Supplement_1):81-88.
-
Oldham JM, Azuma A, Kreuter M, Maher TM, Martinez FJ, Richeldi L, Valenzuela C, Wijsenbeek MS, Liu Y, Zisa D, Zoz DF, Cottin V. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026 05 01; 212(5):972-980.
-
Du M, Peng P, Cao D, Cheng N, Yao L, Sun Y, Li J, Zhang H, Lou G, Tang J, Wang D, Wang Y, Zhang G, Xiang Y. Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study. J Ovarian Res. 2026 Jan 26; 19(1).
-
Wuyts WA, Richeldi L, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Martinez FJ, Valenzuela C, Wijsenbeek MS, Kanakapura M, James A, Weimann G, Drzewuski C, Coeck C, Maher TM. Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis?(FIBRONEER?-ON). BMC Pulm Med. 2025 Dec 04; 26(1):10.
-
Ding S, Yang D, Ullah I, Niu L, Unger M, D?az-Salinas MA, Chandravanshi M, Zhou F, Beaudoin-Bussi?res G, Benlarbi M, Tolbert WD, Yoon K-W, Xu R, Laroche G, Gaudette F, Morton AJ, Lang ZC, Son A, Abrams C, C?t? M, Smith AB, Huang RK, Matthies D, Munro JB, Pazgier M, Uchil PD, Finzi A. Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants. J Virol. 2025 11 25; 99(11):e0103425.
-
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2203-2214.
-
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.
-
Harrold LR, Bingham CO, Pope JE, O'Brien J, Moore PC, Roberts-Toler C, Yu M, Sweet LL, Shelbaya A, Masri KR. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. Clin Rheumatol. 2025 Feb; 44(2):635-648.
-
Vargas-Blanco DA, Hepworth OW, Basham KJ, Simaku P, Crossen AJ, Timmer KD, Hopke A, Brown Harding H, Vandal SR, Jensen KN, Floyd DJ, Reedy JL, Reardon C, Mansour MK, Ward RA, Irimia D, Abramson JS, Vyas JM. BTK inhibitor-induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-a. JCI Insight. 2024 05 07; 9(12).
-
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Coeck C, Schlecker C, Voss F, Wachtlin D, Martinez FJ. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respir Res. 2023 09; 10(1).